Organon & Co. (NYSE:OGN) Hits New 12-Month High – Time to Buy?

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $13.48 and last traded at $13.4850, with a volume of 2868323 shares trading hands. The stock had previously closed at $13.38.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. BNP Paribas Exane restated a “neutral” rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Barclays increased their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 24th. Finally, Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Stock Performance

The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. The stock’s fifty day moving average price is $11.61 and its 200-day moving average price is $8.89. The company has a market capitalization of $3.53 billion, a P/E ratio of 14.47, a PEG ratio of 1.24 and a beta of 1.55.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.02 earnings per share. As a group, research analysts anticipate that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Monday, May 11th were issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, May 11th. Organon & Co.’s dividend payout ratio is currently 8.60%.

Insiders Place Their Bets

In related news, SVP Lynette Holzbaur purchased 26,448 shares of the stock in a transaction on Wednesday, May 6th. The shares were purchased at an average cost of $13.35 per share, with a total value of $353,080.80. Following the acquisition, the senior vice president directly owned 52,851 shares in the company, valued at $705,560.85. The trade was a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Gotham Asset Management LLC raised its holdings in Organon & Co. by 37.2% in the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock valued at $39,657,000 after acquiring an additional 1,007,691 shares during the period. Vanguard Group Inc. increased its holdings in shares of Organon & Co. by 11.3% during the third quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after purchasing an additional 3,650,860 shares during the period. Private Management Group Inc. increased its holdings in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the period. UBS Group AG increased its holdings in shares of Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares during the period. Finally, Kahn Brothers Group Inc. increased its holdings in shares of Organon & Co. by 3.6% during the third quarter. Kahn Brothers Group Inc. now owns 3,616,845 shares of the company’s stock worth $38,628,000 after purchasing an additional 126,695 shares during the period. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.